{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T18:57:26Z","timestamp":1789412246442,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008375","name":"University of Basel","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This study aimed to investigate the prescription rates of low-dose antithrombotic and anti-inflammatory therapies in Germany from 2022 to 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed national outpatient claims data from the German Institute for Drug Use Evaluation. Claims data for patients receiving the following medications were included: aspirin 100\u00a0mg, clopidogrel 75\u00a0mg, prasugrel 5\u00a0mg and 10\u00a0mg, ticagrelor 60\u00a0mg and 90\u00a0mg, rivaroxaban 2.5\u00a0mg, and colchicine 0.5\u00a0mg. Drug utilization was quantified using defined daily doses per 1000 Statutory Health-insured persons per day (DID, 10 DID\u2009=\u2009approximately 1% of the population receive the drug daily).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 2024, aspirin had the highest dispensing volume (47.4 DID), followed by clopidogrel (10.6 DID). All other substances were infrequently prescribed: prasugrel 5\u00a0mg (0.065 DID) and 10\u00a0mg (1.388 DID), ticagrelor 60\u00a0mg (0.103 DID) and 90\u00a0mg (0.978 DID), rivaroxaban 2.5\u00a0mg (1.535 DID), and colchicine (0.457 DID). Rivaroxaban 2.5\u00a0mg was the only drug showing a notable increase in utilization over time (+\u200942% from 2022 to 2024). Cardiologists accounted for a small proportion of prescriptions (mean DID share 3.3%, 1.8% of all dispensed DDD). Aspirin use increased consistently with age, while rivaroxaban 2.5\u00a0mg peaked in the 70\u201374 age group. In contrast, ticagrelor 60\u00a0mg was more frequently prescribed in middle-aged patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite the high prevalence of coronary artery disease (CAD), the use of long-term antithrombotic and anti-inflammatory therapies for secondary prevention in patients with CAD remains low in Germany, especially among older patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                    <jats:p>Temporal trends in the prescription of low dose antithrombotic and anti-inflammatory therapies in Germany (2022\u20132024). ASA\u2009=\u2009aspirin, CAD\u2009=\u2009coronary artery disease, DAPI\u2009=\u2009German Institute for Drug Use Evaluation (Deutsches Arzneipr\u00fcfungsinstitut e.V.), DDD\u2009=\u2009Defined Daily Dose, DID\u2009=\u2009Defined Daily Dose per 1000 inhabitants per day, ESC\u2009=\u2009European society of cardiology, SHI\u2009=\u2009statutory health insurance<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00392-025-02761-x","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T09:51:19Z","timestamp":1759830679000},"page":"1351-1361","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Temporal trends in the prescription of low-dose antithrombotic and anti-inflammatory therapies in Germany (2022\u20132024)"],"prefix":"10.1007","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9666-2209","authenticated-orcid":false,"given":"Michael","family":"Kunz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Espinosa","family":"Daud\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marita","family":"Kieble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Laufs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"G\u00f6tzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper","family":"Boeddinghaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Leibundgut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph R.","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Mahfoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"2761_CR1","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1001\/jama.2010.1322","volume":"304","author":"DL Bhatt","year":"2010","unstructured":"Bhatt DL, Eagle KA, Ohman EM et al (2010) Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 304:1350\u20131357","journal-title":"JAMA"},{"key":"2761_CR2","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMra043430","volume":"352","author":"GK Hansson","year":"2005","unstructured":"Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685\u20131695","journal-title":"N Engl J Med"},{"key":"2761_CR3","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","volume":"383","author":"SM Nidorf","year":"2020","unstructured":"Nidorf SM, Fiolet ATL, Mosterd A et al (2020) Colchicine in patients with chronic coronary disease. N Engl J Med 383:1838\u20131847","journal-title":"N Engl J Med"},{"key":"2761_CR4","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","volume":"381","author":"J-C Tardif","year":"2019","unstructured":"Tardif J-C, Kouz S, Waters DD et al (2019) Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med 381:2497\u20132505","journal-title":"N Engl J Med"},{"key":"2761_CR5","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","volume":"372","author":"MP Bonaca","year":"2015","unstructured":"Bonaca MP, Bhatt DL, Cohen M et al (2015) Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 372:1791\u20131800","journal-title":"N Engl J Med"},{"key":"2761_CR6","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","volume":"377","author":"JW Eikelboom","year":"2017","unstructured":"Eikelboom JW, Connolly SJ, Bosch J et al (2017) Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 377:1319\u20131330","journal-title":"N Engl J Med"},{"key":"2761_CR7","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","volume":"371","author":"L Mauri","year":"2014","unstructured":"Mauri L, Kereiakes DJ, Yeh RW et al (2014) Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371:2155\u20132166","journal-title":"N Engl J Med"},{"key":"2761_CR8","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/S0140-6736(20)31791-8","volume":"396","author":"H-S Kim","year":"2020","unstructured":"Kim H-S, Kang J, Hwang D et al (2020) Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. Lancet 396:1079\u20131089","journal-title":"Lancet"},{"key":"2761_CR9","doi-asserted-by":"publisher","first-page":"e796","DOI":"10.4244\/EIJ-D-25-00331","volume":"21","author":"Y Jang","year":"2025","unstructured":"Jang Y, Park S-D, Lee JP et al (2025) One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial. EuroIntervention 21:e796-809","journal-title":"EuroIntervention"},{"key":"2761_CR10","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","volume":"42","author":"H Thiele","year":"2021","unstructured":"Thiele H, Barbato E, Barthelemy O et al (2021) 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 42:1289\u20131367","journal-title":"Eur Heart J"},{"key":"2761_CR11","first-page":"1","volume":"2023","author":"RA Byrne","year":"2023","unstructured":"Byrne RA, Rossello X, Coughlan JJ et al (2023) ESC Guidelines for the management of acute coronary syndromes. Eur Heart J 2023:1\u2013107","journal-title":"Eur Heart J"},{"key":"2761_CR12","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"C Vrints","year":"2024","unstructured":"Vrints C, Andreotti F, Koskinas KC et al (2024) 2024 ESC guidelines for the management of chronic coronary syndromes. Eur Heart J 45:3415\u20133537","journal-title":"Eur Heart J"},{"key":"2761_CR13","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1097\/HJH.0000000000003789","volume":"42","author":"F G\u00f6tzinger","year":"2024","unstructured":"G\u00f6tzinger F, Kieble M, Daud\u00ed AE et al (2024) Use of fixed-dose combinations for cardiovascular indications from 2018 to 2023: a nationwide population-based study. J Hypertens 42:1720\u20131727","journal-title":"J Hypertens"},{"key":"2761_CR14","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/s41371-020-00425-z","volume":"35","author":"UM Rudolph","year":"2021","unstructured":"Rudolph UM, Enners S, Kieble M et al (2021) Impact of angiotensin receptor blocker product recalls on antihypertensive prescribing in Germany. J Hum Hypertens 35:903\u2013911","journal-title":"J Hum Hypertens"},{"key":"2761_CR15","unstructured":"World Health Organisation.\u00a0Explanation of DID. https:\/\/www.who.int\/tools\/atc-dddtoolkit\/indicators"},{"key":"2761_CR16","unstructured":"Norwegian Institute of Public Health. Use of ATC\/DDD.\u00a0https:\/\/atcddd.fhi.no\/use_of_atc_ddd\/"},{"key":"2761_CR17","unstructured":"Deutsche Apotheker Zeitung. Erstmals Xarelto-Generika im Handel. https:\/\/www.deutscheapotheker-zeitung.de\/news\/artikel\/2024\/04\/18\/erstmals-xarelto-generika-im-handel"},{"key":"2761_CR18","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","volume":"392","author":"GA Roth","year":"2018","unstructured":"Roth GA, Abate D, Abate KH et al (2018) Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392:1736\u20131788","journal-title":"Lancet"},{"key":"2761_CR19","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1093\/eurjpc\/zwab213","volume":"29","author":"S Safiri","year":"2022","unstructured":"Safiri S, Karamzad N, Singh K et al (2022) Burden of ischemic heart disease and its attributable risk factors in 204 countries and territories, 1990\u20132019. Eur J Prev Cardiol 29:420\u2013431","journal-title":"Eur J Prev Cardiol"},{"key":"2761_CR20","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1093\/eurheartj\/ehu505","volume":"36","author":"T Jernberg","year":"2015","unstructured":"Jernberg T, Hasvold P, Henriksson M et al (2015) Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J 36:1163\u20131170","journal-title":"Eur Heart J"},{"key":"2761_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s00103-013-1666-9","author":"A G\u00f6\u00dfwald","year":"2013","unstructured":"G\u00f6\u00dfwald A, Schienkiewitz A, Nowossadeck E et al (2013) Pr\u00e4valenz von Herzinfarkt und koronarer Herzkrankheit bei Erwachsenen im Alter von 40 bis 79 Jahren in Deutschland. Bundesgesundheitsblatt. https:\/\/doi.org\/10.1007\/s00103-013-1666-9","journal-title":"Bundesgesundheitsblatt"},{"key":"2761_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2024.117486","volume":"393","author":"RC Welsh","year":"2024","unstructured":"Welsh RC, Gouda P, Dover D et al (2024) Applicability and impact of the COMPASS trial in a Canadian population of patients with atherosclerotic disease. Atherosclerosis 393:117486","journal-title":"Atherosclerosis"},{"key":"2761_CR23","first-page":"513","volume":"7","author":"L De Luca","year":"2021","unstructured":"De Luca L, Formigli D, Meessen J et al (2021) COMPASS criteria applied to a contemporary cohort of unselected patients with stable coronary artery diseases: insights from the START registry. Eur Heart J 7:513\u2013520","journal-title":"Eur Heart J"},{"key":"2761_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2016-000580","volume":"4","author":"SM Bradley","year":"2017","unstructured":"Bradley SM, Hess GP, Stewart P et al (2017) Implications of the PEGASUS-TIMI 54 trial for US clinical practice. Open Heart 4:e000580","journal-title":"Open Heart"},{"key":"2761_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.1017533","volume":"9","author":"KY Lee","year":"2022","unstructured":"Lee KY, Hwang B-H, Choo E-H et al (2022) Clinical benefit of long-term use of dual antiplatelet therapy for acute myocardial infarction patients with the PEGASUS-TIMI 54 criteria. Front Cardiovasc Med 9:1017533","journal-title":"Front Cardiovasc Med"},{"key":"2761_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwae281","author":"B Chong","year":"2024","unstructured":"Chong B, Jayabaskaran J, Jauhari SM et al (2024) Global burden of cardiovascular diseases: projections from 2025 to 2050. Eur J Prev Cardiol. https:\/\/doi.org\/10.1093\/eurjpc\/zwae281","journal-title":"Eur J Prev Cardiol"},{"key":"2761_CR27","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/S0140-6736(20)30325-1","volume":"395","author":"M Gimbel","year":"2020","unstructured":"Gimbel M, Qaderdan K, Willemsen L et al (2020) Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. Lancet 395:1374\u20131381","journal-title":"Lancet"},{"key":"2761_CR28","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1161\/CIRCULATIONAHA.120.050645","volume":"142","author":"K Szummer","year":"2020","unstructured":"Szummer K, Montez-Rath ME, Alfredsson J et al (2020) Comparison between Ticagrelor and Clopidogrel in elderly patients with an acute coronary syndrome: insights from the SWEDEHEART registry. Circulation 142:1700\u20131708","journal-title":"Circulation"},{"key":"2761_CR29","unstructured":"Zentiva Pharma GmbH (2021) Colchicin Ysat 0.5 mg tablets. Prescribing information"},{"key":"2761_CR30","unstructured":"U.S. Food and Drug Administration FDA (2024) 2023 OND Annual Report - Breaking Barriers to Advance Public Health. FDA"},{"key":"2761_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00508-024-02490-7","volume":"137","author":"R Lunzer","year":"2025","unstructured":"Lunzer R, Delle-Karth G, Zeitlinger M et al (2025) Colchicin - Ph\u00f6nix aus der Asche Colchicine-Phoenix from the ashes. Wien Klin Wochenschr 137:1\u201333","journal-title":"Wien Klin Wochenschr"},{"key":"2761_CR32","first-page":"101622","volume":"4","author":"LF Buckley","year":"2025","unstructured":"Buckley LF, Chebrolu B, Al Zaria M et al (2025) Potential impact of colchicine on atherosclerotic cardiovascular disease in the United States. JACC: Advances 4:101622","journal-title":"JACC: Advances"},{"key":"2761_CR33","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa2405922","volume":"392","author":"SS Jolly","year":"2025","unstructured":"Jolly SS, d\u2019Entremont M-A, Lee SF et al (2025) Colchicine in acute myocardial infarction. N Engl J Med 392:633\u2013642","journal-title":"N Engl J Med"},{"key":"2761_CR34","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s40256-023-00620-6","volume":"24","author":"A Lamy","year":"2024","unstructured":"Lamy A, Eikelboom J, Tong W et al (2024) The cost-effectiveness of Rivaroxaban plus aspirin compared with aspirin alone in the COMPASS trial: a US perspective. Am J Cardiovasc Drugs 24:117\u2013127","journal-title":"Am J Cardiovasc Drugs"},{"key":"2761_CR35","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.jacc.2017.05.063","volume":"70","author":"EA Magnuson","year":"2017","unstructured":"Magnuson EA, Li H, Wang K et al (2017) Cost-effectiveness of long-term ticagrelor in patients with prior myocardial infarction. JACC 70:527\u2013538","journal-title":"JACC"},{"key":"2761_CR36","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ahj.2024.10.011","volume":"279","author":"M Khorsandi","year":"2025","unstructured":"Khorsandi M, Mhaimeed O, Dzaye O et al (2025) Brief report: U.S. trends in use of colchicine by cardiologists and other specialties, 2018 to 2024. Am Heart J 279:76\u201380","journal-title":"Am Heart J"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-025-02761-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-025-02761-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-025-02761-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T07:05:35Z","timestamp":1783494335000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-025-02761-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2761"],"URL":"https:\/\/doi.org\/10.1007\/s00392-025-02761-x","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"21 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CM\n                      has received research support from the Swiss National Science Foundation, the Swiss Heart Foundation, Innosuisse, the University Hospital Basel, the University of Basel; Abbott, Astra Zeneca, Beckman Coulter, Boehringer Ingelheim, BRAHMS Thermo Fisher Scientific, Idorsia, LSI Medience Corporation, Novartis, Ortho Diagnostics, Quidel, Roche, Siemens, Singulex, SpinChip, Sphingotec, and Upstream, all paid to the institution. He has also received speaker honoraria\/consulting honoraria from Abbott, Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, BMS, Daiichi Sankyo, Idorsia, Novartis, Novo Nordisk, Osler, Roche, SpinChip, and Sanofi, again all paid to the institution.\n                      CRM\n                      is supported by the Swiss National Science Foundation and by Innosuisse and has currently ongoing research collaborations with Eli-Lilly, Novartis, and IBSA, all unrelated to this topic.\n                      FG\n                      has been supported by Deutsche Herzstiftung and has received speaker honoraria from AstraZeneca.\n                      FM\n                      has been supported by Deutsche Forschungsgemeinschaft (SFB TRR219, Project-ID 322900939) and Deutsche Herzstiftung. Saarland University has received scientific support from Ablative Solutions, Medtronic, and ReCor Medical. Until May 2024, FM has received speaker honoraria\/consulting fees from Ablative Solutions, AstraZeneca, Inari, Medtronic, Merck, Novartis, Philips, and ReCor Medical.\n                      JB\n                      has been supported by an Edinburgh Doctoral College Scholarship and research grants from the University of Basel, the University Hospital of Basel, the Division of Internal Medicine, the Swiss Academy of Medical Sciences, the Gottfried and Julia Bangerter-Rhyner Foundation, the Swiss National Science Foundation, and the Swiss Heart Foundation, and has received honoraria from Siemens, Roche Diagnostics, Ortho Clinical Diagnostics, Quidel Corporation, and Beckman Coulter, and travel support from Medtronic and Vascularmedical, all outside the submitted work.\n                      MKunz\n                      has received consulting fees from Merck (Merck KGaA).\n                      MS\n                      has received speaker honoraria or consulting fees from Apontis, AstraZeneca, BMS, CSL Vifor, Daiichi Sankyo, Novartis, Pfizer, and TAD, all outside the work submitted.\n                      UL\n                      has received speaker honoraria or consulting fees from Amgen, Boehringer, Daiichi Sankyo, Novartis, Sanofi outside the work submitted.The other authors have nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}